NIMBUS®
Quick-Med’s patented technology, NIMBUS® is a cutting-edge antimicrobial technology that has been custom designed for wound care and other medical applications. NIMBUS® received de Novo FDA clearance in June 2009 and has been commercialized in traditional wound care applications. Additional applications under development include advanced wound dressings, medical adhesives, and catheters.
NIMBUS® is based on non-toxic, long chain polymers with high charge density that provide superior efficacy via a physical action on microbes. By destroying bacteria at the cellular level, NIMBUS® eliminates the risk of developing drug resistance. The technology is highly effective against a multitude of bacteria, including Methicillin-resistant Staphylococcus aureus ("MRSA") and Vancomycin-resistant Enterococcus ("VRE"), two of the most significant antibiotic-resistant organisms responsible for hospital infections.
Unlike any other microbicide on the market today, this cost-effective technology works by creating a non-leaching, permanent bond with a multitude of substrates and is less than 10% the cost of silver-based antimicrobials. NIMBUS® technology enhances the value of treated products and brings dependable, durable and safe antimicrobial protection at extraordinary value—only pennies per product.
Quick-Med has entered licensing agreements with leading wound care companies for NIMBUS® technology with their products. The Company is targeting additional partnerships to apply the NIMBUS® technology in advanced wound care products, catheters, incontinence products and other medical devices.